Nuvectra (NASDAQ: NVTR) is one of 104 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it compare to its rivals? We will compare Nuvectra to related businesses based on the strength of its profitability, valuation, analyst recommendations, dividends, earnings, risk and institutional ownership.
This table compares Nuvectra and its rivals’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Volatility & Risk
Nuvectra has a beta of -2.28, indicating that its share price is 328% less volatile than the S&P 500. Comparatively, Nuvectra’s rivals have a beta of 0.80, indicating that their average share price is 20% less volatile than the S&P 500.
Institutional & Insider Ownership
46.9% of Nuvectra shares are held by institutional investors. Comparatively, 48.0% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 3.6% of Nuvectra shares are held by company insiders. Comparatively, 16.1% of shares of all “Surgical & medical instruments” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Nuvectra and its rivals revenue, earnings per share and valuation.
Nuvectra’s rivals have higher revenue and earnings than Nuvectra. Nuvectra is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This is a summary of recent recommendations and price targets for Nuvectra and its rivals, as reported by MarketBeat.com.
||Strong Buy Ratings
Nuvectra currently has a consensus price target of $12.00, suggesting a potential downside of 12.09%. As a group, “Surgical & medical instruments” companies have a potential upside of 10.74%. Given Nuvectra’s rivals higher possible upside, analysts plainly believe Nuvectra has less favorable growth aspects than its rivals.
Nuvectra rivals beat Nuvectra on 10 of the 12 factors compared.
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs. Its technology platform also has capabilities under development to support other neurological indications, such as sacral nerve stimulation (SNS) and deep brain stimulation (DBS). In addition, its NeuroNexus Technologies, Inc. (NeuroNexus) subsidiary designs, manufactures and markets neural-interface technologies for the neuroscience clinical research market. Its Virtis is an application of the Company’s neurostimulation technology platform and its first product for the SNS market. Its subsidiaries include Algostim, LLC (Algostim) and PelviStim LLC (PelviStim).
Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.